“Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.”, Vaccine, vol. 27, no. 37, pp. 5091-5, 2009.
, “Norovirus vaccine against experimental human Norwalk Virus illness.”, N Engl J Med, vol. 365, no. 23, pp. 2178-87, 2011.
, “Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.”, J Infect Dis, vol. 206, no. 7, pp. 1069-77, 2012.
, “Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised).”, BMC Res Notes, vol. 6, p. 177, 2013.
, “Determination of the 50% human infectious dose for Norwalk virus.”, J Infect Dis, vol. 209, no. 7, pp. 1016-22, 2014.
, “A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.”, J Infect Dis, vol. 210, no. 11, pp. 1763-71, 2014.
, “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.”, JAMA, vol. 314, no. 3, pp. 237-46, 2015.
, “Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.”, J Infect Dis, vol. 211, no. 6, pp. 870-8, 2015.
, “Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
, “Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.”, Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
, “B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.”, Clin Vaccine Immunol, vol. 24, no. 5, 2017.
, “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
, , “Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood.”, Open Forum Infect Dis, vol. 6, no. 1, p. ofy352, 2019.
, “Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.”, Vaccine, vol. 37, no. 19, pp. 2561-2568, 2019.
, “Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.”, Vaccine, vol. 37, no. 36, pp. 5161-5170, 2019.
, “An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine.”, Hum Vaccin Immunother, vol. 16, no. 12, pp. 3138-3145, 2020.
, “Remdesivir for the Treatment of Covid-19 - Preliminary Report.”, N Engl J Med, 2020.
, “Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults.”, J Infect Dis, vol. Online Ahead of Print, 2021.
, “Baricitinib versus Dexamethasone for Adults Hospitalised with COVID-19 (ACTT-4): a Randomised, Double-blind, Double Placebo-controlled Trial”, Lancet Respir Med, vol. 10, no. 9, pp. 888-899, 2022.
, “A Randomized, Controlled Phase 1b Trial of the Sm-TSP-2 Vaccine for Intestinal Schistosomiasis in Healthy Brazilian Adults Living in an Endemic Area”, PLoS Negl Trop Dis, vol. 17, no. 3, p. e0011236, 2023.
,